Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling
Globe Newswire21-02-2023, 13:07
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease 2-10-2025, 18:00